이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

Use of mHealth Application and Education to Increase Appropriateness of Thromboprophylaxis in Patients With Cancer

2026년 11월 5일 업데이트: Javier Ena, Universidad Miguel Hernandez de Elche

mHealth-supported Education Improves Thromboprophylaxis Appropriateness in Solid Tumors

Doctors will use a mHealth application to evaluate the risk of thrombosis and bleeding in patients with cancer.

연구 개요

상세 설명

This information will be shared with the patients to make an informed decision of using low molecular weight prophylaxis with heparin in case of high risk thrombosis a low-moderate risk of bleeding

연구 유형

중재적

등록 (실제)

180

단계

  • 해당 없음

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 장소

    • Alicante
      • Villajoyosa, Alicante, 스페인, 03570
        • Hospital Marina Baixa

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

18년 이상 (성인, 고령자)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

모두

설명

Inclusion Criteria:

  • Age 18 years or older, and
  • Recent diagnosis of a solid tumor or disease progression after partial or complete remission, and.
  • Starting a new course of systemic anticancer therapy (chemotherapy, targeted therapy, hormone therapy, or immunotherapy) planned for at least 3 months

Exclusion Criteria:

  • High risk of bleeding (e.g., advanced liver disease with coagulopathy), or
  • Life expectancy under 3 months, or
  • Hematologic malignancies, or
  • Estimated glomerular filtration rate below 30 mL/min/1.73 m², or
  • Platelet count below 50,000/mm³, or
  • Body weight below 40 kg, or
  • Current anticoagulant use.

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 건강 서비스 연구
  • 할당: 무작위화되지 않음
  • 중재 모델: 순차적 할당
  • 마스킹: 없음(오픈 라벨)

무기와 개입

참가자 그룹 / 팔
개입 / 치료
간섭 없음: Control group (preintervention)

Inclusion criteria:

  • Age 18 or oler
  • Recent diagnosis of solid tumor or disease progression after partial or complete remission.
  • Starting a new course of systemic anticancer therapy-chemotherapy, targeted therapy, hormone therapy, or immunotherapy-planned to last at least 3 months.

Exclusion criteria:

  • High risk of bleeding (e.g., advanced liver disease with coagulopathy)
  • Life expectancy of less than 3 months
  • Hematologic malignancy
  • Estimated glomerular filtration rate below 30 mL/min/1.73 m²
  • Platelet count below 50,000/mm³
  • Weighed less than 40 kg
  • Currently receiving anticoagulation.

In the preintervention period, we reviewed the electronic medical records of patients with a recent cancer diagnosis who were seen between January and June 2024.

활성 비교기: postintervention

After using the mHealth application, the treating physician made the final decision regarding use of thromboprophylaxis after considering risk of thromboembolic disease, bleeding risk, renal function, drug interactions, and patient preferences.

Postintervention period. For patients with cancer seen between January and June 2025, we collected the same variables from the electronic medical records as in the preintervention period. We selected the same calendar months to control for seasonality and enhance comparability between periods

Physicians from the Internal Medicine and Oncology divisions attended a 2-hour session reviewing current guidelines for thromboprophylaxis in patients with cancer, followed by training on the mHealth TEVAPP application. TEVAPP is a web-based calculator of venous thromboembolism (VTE) risk scores for patients with cancer, developed by the Spanish Society of Medical Oncology (SEOM) (Spain; https://tevapp.es/; accessed December 15, 2024). The application was used to support clinical decision-making by integrating available clinical, laboratory, and treatment information at the initial visit before the initiation of a new systemic regimen.

TEVAPP is a web-based calculator of VTE risk scores for patients with cancer, developed by SEOM (Spain; https://tevapp.es/; accessed December 15, 2024). It was used to support clinical decisions by integrating available clinical, laboratory, and treatment information at the initial visit before a new systemic regimen

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Proprtion of patients with appropriate thromboprophylaxis use
기간: From first visit to oncology clinic up to three month of follow up

The primary outcome was the proportion of patients with appropriate prescription of thromboprophylaxis from the first medical oncology visit in the pre- and postintervention periods. The appropriateness of thromboprophylaxis was determined according to clinical practice guideline recommendations. Thromboprophylaxis was considered appropriate when weight-adjusted enoxaparin was prescribed for patients at intermediate or high thrombotic risk (6-month VTE probability >8%) and low bleeding risk, in the absence of other contraindications. Low bleeding risk was defined as an IMPROVE score <7 for patients hospitalized within the previous 30 days, or a Hokusai score <3 for nonhospitalized patients. In the version of TEVAPP used, the latter corresponded to fewer than 60% of bleeding risk factors. Withholding thromboprophylaxis was considered appropriate for patients at low thrombotic risk or with contraindications to anticoagulation.

From first visit to oncology clinic up to three month of follow up

2차 결과 측정

결과 측정
측정값 설명
기간
Incidence of venous thromboembolic disease
기간: From first visit the the Oncology Clinic up to three months of follow-up

We compared the incidence of VTE disease in the pre- and postintervention periods.

VTE is suspected based on clinical symptoms and signs and confirmed with objective testing. The diagnostic approach includes assessment of pretest clinical probability, selective D-dimer testing, and imaging.

Suspected DVT: Clinical probability is estimated using the 2-level Wells score. Patients with a likely score (≥2 points) should undergo proximal leg-vein compression ultrasonography, preferably with Doppler assessment; D-dimer may be used selectively when ultrasound is negative or clinical probability is low.

Suspected PE: Clinical probability is estimated using a validated score such as the Wells score. Definitive diagnosis is usually made with computed tomography pulmonary angiography (CTPA); a ventilation-pe

From first visit the the Oncology Clinic up to three months of follow-up
Incidence of bleeding
기간: From first visit the the Oncology Clinic up to three months of follow-up

We compared the bleeding events in the pre- and postintervention periods classified according to the International Society on Thrombosis and Haemostasis (ISTH) criteria. Major bleeding was defined as fatal bleeding, symptomatic bleeding in a critical site or organ (intracranial, intraspinal, intraocular, retroperitoneal, intra-articular, or pericardial bleeding, or intramuscular bleeding with compartment syndrome), or bleeding associated with a hemoglobin decrease of ≥2 g/dL or transfusion of ≥2 units of whole blood or packed red blood cells. Clinically relevant non-major bleeding was defined as overt bleeding not meeting major bleeding criteria but requiring hospitalization, medical or surgical intervention, or interruption or modification of anticoagulant therapy

From first visit the the Oncology Clinic up to three months of follow-up
Incidence of death
기간: From first visit the the Oncology Clinic up to three months of follow-up

We compared all-cause mortality in the pre- and postintervention periods. All-cause mortality was defined as death from any cause occurring during the study follow-up period.

From first visit the the Oncology Clinic up to three months of follow-up

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

수사관

  • 수석 연구원: Javier Ena, MD, Hospital Marina Baixa

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (실제)

2024년 1월 1일

기본 완료 (실제)

2025년 9월 30일

연구 완료 (실제)

2025년 12월 30일

연구 등록 날짜

최초 제출

2026년 10월 29일

QC 기준을 충족하는 최초 제출

2026년 11월 5일

처음 게시됨 (실제)

2026년 11월 12일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 11월 12일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 11월 5일

마지막으로 확인됨

2026년 11월 1일

추가 정보

이 연구와 관련된 용어

추가 관련 MeSH 약관

기타 연구 ID 번호

  • Univeridad Miguel Hernandez
  • UGP-24-212 (기타 보조금/기금 번호: Fundación Eugenio Rodriguez Pascual)

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

예

IPD 계획 설명

Upon reasonable request with patient de-identification

IPD 공유 기간

October 2026, to October 2027

IPD 공유 액세스 기준

Javier Ena, MD. Personal computer

IPD 공유 지원 정보 유형

  • 연구_프로토콜
  • 수액

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

아니

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .

구독하다